Literature DB >> 28123170

Clinicopathological Features and Prognosis of Intrahepatic Cholangiocarcinoma After Liver Transplantation and Resection.

Dong-Hwan Jung1, Shin Hwang1, Gi-Won Song1, Chul-Soo Ahn1, Deok-Bog Moon1, Ki-Hun Kim1, Tae-Yong Ha1, Gil-Chun Park1, Seung-Mo Hong2, Wan-Jun Kim1, Woo-Hyoung Kang1, Seok-Hwan Kim1, Eun Sil Yu1, Sung-Gyu Lee1.   

Abstract

BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be incidentally diagnosed after liver transplantation (LT). We investigated the clinicopathological features of LT recipients with ICC and compared prognosis with that of the control group. MATERIAL AND METHODS We identified 16 recipients with ICC in our institutional database. The propensity score-matched control group comprised 100 ICC patients who underwent hepatic resection (HR). RESULTS ICC incidence was 0.5% in all adult LT patients and 1.2% in adult recipients with primary liver cancer. Mean age was 58.0±4.8 years and 15 were male. All ICCs were diagnosed incidentally in the explanted livers. Mean ICC tumor diameter was 2.5±1.1 cm and 14 recipients had a single tumor. Tumor stages were I in 9, II in 5, and IV in 2. Concurrent second primary liver cancer was detected as hepatocellular carcinoma in 7 and combined hepatocellular carcinoma-cholangiocarcinoma in 1. Tumor recurrence and patient survival rates were 56.2% and 81.3% at 1 year and 78.1% and 52.4% at 5 years, respectively. Presence of second cancer did not affect tumor recurrence (p=0.959) or patient survival (p=0.737). All 3 patients with very early ICC did not show ICC recurrence. Compared with the control group, the tumor recurrence rate was higher after LT (p=0.024), but this difference disappeared after analysis was confined to recipients with ICC alone (p=0.121). Post-recurrence survival was not different after HR and LT (p=0.082). CONCLUSIONS ICC is rarely diagnosed after LT and half of such patients have second liver cancer. Post-transplant prognosis of ICC is poor except for very early ICC; thus, strict surveillance is mandatory.

Entities:  

Mesh:

Year:  2017        PMID: 28123170     DOI: 10.12659/aot.901504

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  3 in total

1.  Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy?

Authors:  Chen Jin; Xiao-Yun Zhang; Jia-Wu Li; Chuan Li; Wei Peng; Tian-Fu Wen; Yan Luo; Qiang Lu; Xiao-Fei Zhong; Jing-Yi Zhang; Lv-Nan Yan; Jia-Yin Yang
Journal:  Oncotarget       Date:  2017-07-27

2.  Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Authors:  Gil Chun Park; Shin Hwang; Chul Soo Ahn; Ki Hun Kim; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Young In Yoon; Hui Dong Cho; Jae Hyun Kwon; Yong Kyu Chung; Sang Hyun Kang; Jin Uk Choi; I Ji Jung; Sung Gyu Lee
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

3.  Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma.

Authors:  Falk Rauchfuß; Aladdin Ali-Deeb; Oliver Rohland; Felix Dondorf; Michael Ardelt; Utz Settmacher
Journal:  Curr Oncol       Date:  2022-03-13       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.